Your session is about to expire
← Back to Search
Janus kinase (JAK) inhibitor
Tofacitinib for Ulcerative Colitis (TRIUMPH Trial)
Phase 2
Waitlist Available
Led By Neeraj Narula, MD
Research Sponsored by McMaster University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 7 days
Awards & highlights
All Individual Drugs Already Approved
No Placebo-Only Group
Approved for 10 Other Conditions
Summary
This trial will study whether tofacitinib can help treat ulcerative colitis in hospitalized patients.
Eligible Conditions
- Flare Up
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 7 days
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~7 days
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Clinical response at day 7
Awards & Highlights
All Individual Drugs Already Approved
Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Approved for 10 Other Conditions
This treatment demonstrated efficacy for 10 other conditions.
Trial Design
1Treatment groups
Experimental Treatment
Group I: Treatment armExperimental Treatment1 Intervention
Tofacitinib 10mg PO BID
Find a Location
Who is running the clinical trial?
McMaster UniversityLead Sponsor
916 Previous Clinical Trials
2,615,235 Total Patients Enrolled
University of ManitobaOTHER
618 Previous Clinical Trials
206,685 Total Patients Enrolled
University of British ColumbiaOTHER
1,465 Previous Clinical Trials
2,485,473 Total Patients Enrolled
Share this study with friends
Copy Link
Messenger